2024 Partners
Promega
Expertise Partner
Promega is committed to excellence in technologies and compound profiling services to assess key processes in Targeted Protein Degradation and Induced Proximity mechanisms. From assessing protein degradation in real time, to understanding compound binding and permeability, to ternary complex formation and more. Our CRIPSR HiBiT content covers hundreds of pre-built targets. Novel software analysis tools allow for the determination of target protein degradation rates, DC50 potency values, recovery profiles and more.
Applied BioMath
Expertise Partner
Applied BioMath applies biosimulation services and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Applied BioMath recently joined Certara in a strategic acquisition to form the life sciences industry's largest team of experts in quantitative systems pharmacology (QSP). Certara’s clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Biortus
Event Partner
Biortus is a structure-based drug discovery CRO with a mature protein focused lead generation platform including modular services in protein production, assay development, fragment screening, and structure determination in microED, CryoEM, and X-ray crystallography. We’ve solved structures of some ternary degradation complexes including VHL and CRBN based PROTACs. Our newest Boston site is available for 2-way sample shipment and serves as the headquarters for our off-the-shelf Protein Catalog which includes DUBS, E3 ligases, and more.
Rapafusyn
Industry Partner
Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore, Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from John Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfil unmet medical needs.
Here is What Some of the Leaders of the Field Have to Say About this Meeting:
‘This meeting provides a great platform for people working in the cutting-edge of the molecular glue field to exchange ideas and inspire new collaborations’
Kun Song, Associate Principal Scientist- Computational Chemistry, AstraZeneca
‘This is a unique opportunity to showcase Plexium’s unique high-throughput and high-dimensional approach to unbiased identification of E3 ligase redirection events, in the context of industry leaders in the field of TPD’,
Tomas Duffy, Principal Scientist, Plexium
‘This meeting is an excellent opportunity to hear the latest relevant research, reconnect with previous co-workers, and meet new colleagues, all of which facilitate initiating partnerships to accelerate scientific and therapeutic discoveries’
Ingrid Wertz, Chief Executive Officer & Co-Founder, Lyterian Therapeutics
‘As recent advances of degrading molecular glues from the bench to the clinic significantly expand the druggable target space, the discussion topics of non-degrading and stabilizing molecular glues come at an opportune time to further stir up interests of these approaches that will further expand the arsenal of the drug discovery community to target the “undruggable” space’
Yongxin Han, Executive Vice President & Head of Drug Discovery, Nested Therapeutics
